Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 70Tumor-Agnostic 3Head & Neck 3Gastrointestinal 3CNS 3Breast 3Plasma cell 2Other solid neoplasm 2Other hematologic neoplasm 2Lymphoid 2Gynecologic 2Genitourinary 2Endocrine 1Dermatologic 1

Conditions

Solid Tumor 1Mesothelioma 1

Interventions

pembrolizumab 33Injections 28Pemetrexed 15Interviews as Topic 15Carboplatin 14tislelizumab 13Cisplatin 13Specimen Handling 12Bevacizumab 11atezolizumab 10Nivolumab 10Practice Guidelines as Topic 9Educational Status 9Cyclophosphamide 9Standard of Care 8Oxaliplatin 8Fluorouracil 8fludarabine 7Methods 7Early Intervention, Educational 7Docetaxel 7Cetuximab 7Capecitabine 7toripalimab 6sotorasib 6Paclitaxel 6Leucovorin 6olaparib 5Platinum 5Ipilimumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
osimertinib × Other solid neoplasm × 90 days × Clear all
NCT07612137 2026-05-28

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Not yet recruiting
282 enrolled
Other solid neoplasm

Solid Tumor

NCT04665206 2026-04-02

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Vivace Therapeutics, Inc

Phase 1/2 Recruiting
434 enrolled
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡